UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-Acting Injectables Come of Age to Change the HIV Therapeutic Landscape and the Lives of Persons with HIV

AIDS research and human retroviruses, 2021-03, Vol.37 (3), p.169-170

Smith, Kimberly Y.

2021

Volltextzugriff (PDF)

Challenges and Successes in Linking HIV-Infected Women to Care in the United States

Clinical infectious diseases, 2011-01, Vol.52 (suppl_2), p.S231-S237

2011

Volltextzugriff (PDF)

Paying the Price for Late Starts and Early Stops: Racial and Sex Disparities in HIV-Related Mortality

Clinical infectious diseases, 2009-11, Vol.49 (10), p.1579-1581

Smith, Kimberly Y.

2009

Volltextzugriff (PDF)

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10101), p.1499-1510

2017

Volltextzugriff (PDF)

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Journal of acquired immune deficiency syndromes (1999), 2020-03, Vol.83 (3), p.310-318

2020

Volltextzugriff (PDF)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

AIDS (London), 2022-01, Vol.36 (1), p.39-48

2022

Volltextzugriff (PDF)

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL

Clinical infectious diseases, 2018-05, Vol.66 (11), p.1689-1697

2018

Volltextzugriff (PDF)

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

AIDS (London), 2022-02, Vol.36 (2), p.185-194

2022

Volltextzugriff (PDF)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

AIDS research and therapy, 2008-03, Vol.5 (1), p.5-5

2008

Volltextzugriff (PDF)

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

Journal of acquired immune deficiency syndromes (1999), 2020-11, Vol.85 (3), p.325-330

2020

Volltextzugriff (PDF)

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196

Journal of acquired immune deficiency syndromes (1999), 2024-06, Vol.96 (2), p.156-160

2024

Volltextzugriff (PDF)

Addressing disparities in HIV mortality: antiretroviral therapy is necessary but not sufficient

Clinical infectious diseases, 2013-06, Vol.56 (12), p.1810-1811

Smith, Kimberly Y

2013

Volltextzugriff (PDF)

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

The patient : patient-centered outcomes research, 2021-11, Vol.14 (6), p.849-862

2021

Volltextzugriff (PDF)

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

Journal of acquired immune deficiency syndromes (1999), 2020-05, Vol.84 (1), p.60-65

2020

Volltextzugriff (PDF)

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

AIDS (London), 2009-07, Vol.23 (12), p.1547-1556

2009

Volltextzugriff (PDF)

Thymic Size and Lymphocyte Restoration in Patients with Human Immunodeficiency Virus Infection after 48 Weeks of Zidovudine, Lamivudine, and Ritonavir Therapy

The Journal of infectious diseases, 2000-01, Vol.181 (1), p.141-147

2000

Volltextzugriff (PDF)

1 – 25 von 265

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(214)

Publikationsform

Artikel
(247)
Buchkapitel
(14)
Bücher
(4)

Sprache

Englisch
(262)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

Long-Acting Injectables Come of Age to Change the HIV Therapeutic Landscape and the Lives of Persons with HIV

Challenges and Successes in Linking HIV-Infected Women to Care in the United States

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Paying the Price for Late Starts and Early Stops: Racial and Sex Disparities in HIV-Related Mortality

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196

Addressing disparities in HIV mortality: antiretroviral therapy is necessary but not sufficient

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

Thymic Size and Lymphocyte Restoration in Patients with Human Immunodeficiency Virus Infection after 48 Weeks of Zidovudine, Lamivudine, and Ritonavir Therapy

Suchergebnisse filtern